• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
20OctOctober 20, 2023

Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2-Advanced Breast Cancer: Update of Dose Escalation Results From a Phase 1/2 Trial

02JunJune 2, 2023

TACTIVE-U: Phase 1b/2 Umbrella Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined with Other Anticancer Treatments in ER+ Advanced or Metastatic Breast Cancer

02JunJune 2, 2023

VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

11MayMay 11, 2023

TACTIVE-N: Open-Label, Randomized, Noncomparative Neoadjuvant Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal Women with ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Localized Breast Cancer

11MayMay 11, 2023

VERITAC Update: Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

11MayMay 11, 2023

TACTIVE-E: Phase 1b Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination with Everolimus in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

11MayMay 11, 2023

VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

14AprApril 14, 2023

Mechanisms of Acquired Resistance to ARV-471, a Novel PROTAC® Estrogen Receptor Degrader

14AprApril 14, 2023

Enhanced Efficacy of ARV-471, a Novel PROTAC® Estrogen Receptor Degrader, in Combination with Targeted Agents in Estrogen Receptor-Positive (ER+) Breast Cancer Models

  Prev1…34
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE